If you have been reading about melanotan-2 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
=== Facilities === As of 2013, GSK had offices in over 115 countries and employed over 99,000 people, 12,500 in R&D. The company's single largest market is the United States. Its US headquarters are in Philadelphia, Pennsylvania and Durham, North Carolina; its consumer-products division is in Moon Township, Pennsylvania.
Ions can be created in an electric glow discharge. A glow discharge is a plasma formed by the passage of electric current through a low-pressure gas. It is created by applying a voltage between two metal electrodes in an evacuated chamber containing gas. When the voltage exceeds a certain value, called the striking voltage, the gas forms a plasma. A duoplasmatron is a type of glow discharge ion source that consists of a hot cathode or cold cathode that produces a plasma that is used to ionize a gas. They can produce positive or negative ions. They are used for secondary ion mass spectrometry, ion beam etching, and high-energy physics.
4-HO-EPT, also known as 4-hydroxy-N-ethyl-N-propyltryptamine or as eprocin, is a psychedelic drug of the tryptamine family, which is structurally related to psilocin (4-HO-DMT). It was encountered as a novel designer drug in Japan by 2021.
23793Np + 4820Ca → 285113* → 282113 + 3 n Two atoms of 282113 were detected. The aim of this experiment had been to synthesise the isotopes 281113 and 282113 that would fill in the gap between isotopes produced via hot fusion (283113 and 284113) and cold fusion (278113). After five alpha decays, these nuclides would reach known isotopes of lawrencium, assuming that the decay chains were not terminated prematurely by spontaneous fission. The first decay chain ended in fission after four alpha decays, presumably originating from 266Db or its electron-capture daughter 266Rf. Spontaneous fission was not observed in the second chain even after four alpha decays. A fifth alpha decay in each chain could have been missed, since 266Db can theoretically undergo alpha decay, in which case the first decay chain would have ended at the known 262Lr or 262No and the second might have continued to the known long-lived 258Md, which has a half-life of 51.5 days, longer than the duration of the experiment: this would explain the lack of a spontaneous fission event in this chain. In the absence of direct detection of the long-lived alpha decays, these interpretations remain unconfirmed, and there is still no known link between any superheavy nuclides produced by hot fusion and the well-known main body of the chart of nuclides.
Sources: en.wikipedia.org
== Taxonomy == Tricholoma equestre was known to Carl Linnaeus, who officially described it in Volume Two of his Species Plantarum in 1753, giving it the name Agaricus equestris, predating a description of Agaricus flavovirens by Persoon in 1793. Thus this specific name meaning "of or pertaining to horses" in Latin takes precedence over Tricholoma flavovirens, the other scientific name by which this mushroom has been known. It was placed in the genus Tricholoma by German Paul Kummer in his 1871 work Der Führer in die Pilzkunde. The generic name derives from the Greek trichos/τριχος 'hair' and loma/λωμα 'hem', 'fringe' or 'border'. Common names include the man-on-horseback, yellow knight, and saddle-shaped tricholoma.
== Worldwide incidence by country == The total number of centenarians in the world is uncertain. The Population Division of the United Nations estimated that there were 23,000 in 1950, 110,000 in 1990, 150,000 in 1995, 209,000 in 2000, 324,000 in 2005, 455,000 in 2009, 675,000 in 2019 and 935,000 in 2024. These older estimates, however, did not take into account downward adjustments of national estimates made by several countries such as the United States. The UN estimated in 2012, as a result of these adjustments, that there were only 316,600 centenarians worldwide. The following table gives estimated centenarian populations by country, including both the latest and the earliest known estimates, where available. A study which received a 2024 Ig Nobel Prize found these numbers are inflated by welfare and pension fraud and poor record-keeping, neither of which are uniform across jurisdictions.
For many years, arsenic trioxide was administered to patients with various cancers, showing the best results in the treatment of acute promyelocytic leukemia. More than half of the patients from the first trial in Harbin survived for five years, prompting further research across other centers in China, and eventually at the Sloan-Kettering Memorial Institute in New York. The results of clinical trials were favorable enough that in 2000, the drug received FDA approval.
=== Dopamine === For example, problems in producing dopamine (mainly in the substantia nigra) can result in Parkinson's disease, a disorder that affects a person's ability to move as they want to, resulting in stiffness, tremors or shaking, and other symptoms. Some studies suggest that having too little or too much dopamine or problems using dopamine in the thinking and feeling regions of the brain may play a role in disorders like schizophrenia or attention deficit hyperactivity disorder (ADHD). Dopamine is also involved in addiction and drug use, as most recreational drugs cause an influx of dopamine in the brain (especially opioid and methamphetamines) that produces a pleasurable feeling, which is why users constantly crave drugs.
Once again, RuBisCO activase can promote the release of these analogs from the catalytic sites and maintain the enzyme in a catalytically active form. However, at high temperatures, RuBisCO activase aggregates and can no longer activate RuBisCO. This contributes to the decreased carboxylating capacity observed during heat stress.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.